Xeris Pharmaceuticals (XERS) IPO Opens 5% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Xeris Pharmaceuticals (XERS) Reports Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen
June 25, 2018 4:16 PM EDTXeris Pharmaceuticals, Inc. (NASDAQ: XERS) today announced the presentation of positive results from two of its Phase 3 clinical studies on its investigational ready-to-use, room-temperature stable liquid glucagon rescue pen during oral and poster sessions at the American Diabetes Associations (ADA) 78th Scientific Sessions, June 22-26, 2018.
The data presentations highlight the efficacy and safety data from studies of the Xeris ready-to-use glucagon rescue pen in treating severe hypoglycemia in adults and children with type 1 diabetes, as compared to the currently marketed Glucagon Emergency Kit (GEK).
In addition to the Phase 3 study results... More
Xeris Pharmaceuticals, Inc. (XERS) Prices 5.7M Shares IPO at $15/Sh
June 21, 2018 6:29 AM EDTXeris Pharmaceuticals, Inc. (NASDAQ: XERS) today announced the pricing of the Companys initial public offering of 5,700,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts, for gross proceeds of $85.5 million. All of the shares are being offered by... More
